Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBluecross Idaho Etelcalcetide Prior Auth | OpenPay…
    Ask Trek AI about this page
    CurrentBluecross IdahoPolicy MP 5.01.652

    Etelcalcetide (Parsabiv) for Secondary Hyperparathyroidism

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy MP 5.01.652 alerts

    Get alerted when Policy MP 5.01.652 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and prior authorization for etelcalcetide used to treat secondary hyperparathyroidism in adults with chronic kidney disease receiving hemodialysis. Coverage requires specified clinical, laboratory, treatment, and renewal criteria and is subject to the member-specific benefit plan.

    Policy Summary
    PayerBluecross Idaho
    PolicyEtelcalcetide (Parsabiv) for Secondary Hyperparathyroidism
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMay 28, 2026
    Last ReviewMay 28, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document that all six initial criteria are met before initiating etelcalcetide.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥18Minimum age
    3×/weekHemodialysis history
    ≥400PTH threshold
    6 monthsApproval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥30%
    Renewal PTH reduction

    Coverage Criteria

    Initial Therapy

    Etelcalcetide may be considered medically necessary if ALL of the following criteria are met:

    Initial therapy criteria

    • Disease status: The patient is diagnosed with chronic kidney disease (CKD) and is currently receiving hemodialysis three times weekly for at least the previous three months.Hemodialysis 3 times weekly for ≥3 months
    • Disease severity: The patient has moderate to severe hyperparathyroidism.PTH ≥400 mg/ml
    • Age: The patient is at least 18 years of age.≥18 years
    • Calcium status: The patient has a corrected calcium level at or above the lower limit of normal prior to initiation.≥8.3 mg/dl
    • Concomitant therapy: The patient is taking stable doses of active vitamin D analogs, calcium supplements, or phosphate binders.

    Continuation/Renewal Therapy

    Etelcalcetide will be approved for renewal when ALL of the following criteria are met:

    Continuation/renewal criteria

    • Treatment response: The patient has at least a 30% reduction from baseline in mean parathyroid hormone.≥30% reduction from baseline
    • Prior authorization history: The patient has been previously approved through the Blue Cross of Idaho prior authorization process.
    • Safety: The member does not have unacceptable toxicity to Parsabiv, including severe hypocalcemia, ventricular arrhythmia, seizures, heart failure, and upper gastrointestinal bleeding.No unacceptable toxicity

    All other uses of etelcalcetide are considered investigational, including uses that do not meet the specified criteria for chronic kidney disease, hemodialysis, moderate-to-severe hyperparathyroidism, adult age, adequate corrected calcium, and stable concomitant therapy.

    ESRD facilities will not be responsible for furnishing calcimimetics, including etelcalcetide, to individuals with acute kidney injury (AKI).

    Coding and Clinical Thresholds

    HCPCSHCPCS
    J0606Injection, etelcalcetide, 0.1 mg to ESRD beneficiaries, ESRD facilities will not be responsible for furnishing calcimimetics to individuals with AKI.
    Parathyroid Hormone Threshold
    Threshold≥400 mg/ml
    ConditionModerate to severe hyperparathyroidism
    ApplicationRequired before initial etelcalcetide coverage
    Corrected Calcium Requirement
    Minimum levelAt or above the lower limit of normal
    Numeric threshold≥8.3 mg/dl
    TimingRequired prior to initiation

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization Required

    Prior authorization is required for initial etelcalcetide (Parsabiv) therapy. Approval may be granted for 6 months when all six initial medical-necessity criteria are met.

    • Diagnosis of chronic kidney disease (CKD).
    • Currently receiving hemodialysis three times weekly for at least the preceding 3 months.
    • Moderate to severe hyperparathyroidism with PTH greater than or equal to 400 mg/ml.
    • Age 18 years or older.
    • Corrected calcium at or above the lower limit of normal before initiation (equal to or greater than 8.3 mg/dl).
    • Stable doses of active vitamin D analogs, calcium supplements, or phosphate binders.
    Prior Authorization

    Renewal Authorization Required

    Renewal authorization is required after each 6-month approval period. Renewal requires a response to therapy, prior approval through the Blue Cross of Idaho prior authorization process, and no unacceptable toxicity to Parsabiv.

    Clinical Background

    Etelcalcetide is a calcimimetic that increases the sensitivity of the calcium-sensing receptor to extracellular calcium, thereby reducing parathyroid hormone synthesis and secretion. It is indicated for secondary hyperparathyroidism in adults with chronic kidney disease who are receiving hemodialysis. Reduced parathyroid hormone may decrease bone turnover and bone fibrosis in patients with uncontrolled secondary hyperparathyroidism. Treatment carries potential risks related to calcium balance, corrected QT prolongation, and sudden death.

    Definitions

    Etelcalcetide (Parsabiv)
    MedicationEtelcalcetide (Parsabiv)
    Drug classCalcium-sensing receptor agonist; calcimimetic agent
    IndicationTreatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis
    Secondary Hyperparathyroidism
    ConditionSecondary hyperparathyroidism
    CharacteristicElevated parathyroid hormone in patients with chronic kidney disease
    Relevant populationParticularly patients receiving hemodialysis

    Initial Therapy Criteria

    Initial Therapy

    Initial therapy may be considered medically necessary when ALL of the following criteria are met:

    Initial etelcalcetide criteria

    • Disease status: The patient is diagnosed with chronic kidney disease (CKD).
    • Hemodialysis: The patient is currently receiving hemodialysis three times weekly for at least the previous three months.3 times weekly for ≥3 months
    • Disease severity: The patient has a diagnosis of moderate to severe hyperparathyroidism.PTH ≥400 mg/ml

    Continuation Therapy Criteria

    Continuation Therapy

    Renewal is approved when ALL of the following criteria are met:

    Continuation therapy criteria

    • Treatment response: The patient has at least a 30% reduction from baseline in mean parathyroid hormone.≥30% reduction from baseline
    • Prior authorization history: The patient has been previously approved through the Blue Cross of Idaho prior authorization process.
    • Safety: The member does not have unacceptable toxicity to Parsabiv, including severe hypocalcemia, ventricular arrhythmia, seizures, heart failure, and upper gastrointestinal bleeding.No unacceptable toxicity

    Quantity Limits

    Initial Authorization Quantity Limit
    MedicationEtelcalcetide
    Quantity limit6 per month
    Initial approval period6 months
    Continuation Authorization Quantity Limit
    MedicationEtelcalcetide
    Quantity limit6 per month
    Renewal approval period6 months

    Site of Care and Administration

    Note

    Administer at the end of hemodialysis

    Administer etelcalcetide intravenously as a bolus three times per week at the end of hemodialysis.

    • Site of care: infusion center.
    • Initial dosing is 5 mg IV bolus three times per week at the end of hemodialysis.
    Policy Summary
    PayerBluecross Idaho
    PolicyEtelcalcetide (Parsabiv) for Secondary Hyperparathyroidism
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMay 28, 2026
    Last ReviewMay 28, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document that all six initial criteria are met before initiating etelcalcetide.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsAuthorization and Documentation RequirementsClinical BackgroundDefinitionsInitial Therapy CriteriaContinuation Therapy CriteriaQuantity LimitsSite of Care and Administration
    Renewal PTH Response
    Required response≥30% reduction in mean parathyroid hormone
    Comparison pointFrom baseline
    ApplicationRequired for renewal approval
    • At least a 30% reduction from baseline in mean parathyroid hormone.
    • The member was previously approved through the Blue Cross of Idaho prior authorization process.
    • The member does not have unacceptable toxicity to Parsabiv.
    Documentation Required

    Initial Clinical Documentation

    Submit clinical documentation supporting every initial criterion before etelcalcetide is initiated. The record should establish the diagnosis, dialysis history, hyperparathyroidism severity, age, corrected calcium status, and stable concomitant treatment.

    • CKD diagnosis.
    • Hemodialysis three times weekly for at least the previous 3 months.
    • PTH level demonstrating moderate to severe hyperparathyroidism (greater than or equal to 400 mg/ml).
    • Patient age of at least 18 years.
    • Pre-initiation corrected calcium equal to or greater than 8.3 mg/dl, at or above the lower limit of normal.
    • Current stable doses of active vitamin D analogs, calcium supplements, or phosphate binders.
    Documentation Required

    Renewal Documentation

    For renewal, document the member’s response to etelcalcetide and the prior authorization history. The submission must support the required PTH response and confirm that the member has no unacceptable Parsabiv toxicity.

    • Mean parathyroid hormone decreased by at least 30% from baseline.
    • Prior approval through the Blue Cross of Idaho prior authorization process.
    • Assessment documenting absence of severe hypocalcemia, ventricular arrhythmia, seizures, heart failure, and upper gastrointestinal bleeding.

    Unsupported block type: denial_risk。在_INTERNAL_

    Denial Risk

    Renewal Criteria Not Met

    Renewal should not be approved when the required response, prior approval, or safety conditions are not met.

    • Mean parathyroid hormone reduction is less than 30% from baseline.
    • The member was not previously approved through the Blue Cross of Idaho prior authorization process.
    • The member has unacceptable toxicity to Parsabiv.
    Denial Risk

    Unacceptable Toxicity

    Do not continue or renew etelcalcetide when unacceptable toxicity is present. The renewal criteria specifically identify the following safety concerns.

    • Severe hypocalcemia.
    • Ventricular arrhythmia.
    • Seizures.
    • Heart failure.
    • Upper gastrointestinal bleeding.
    Billing Rule

    AKI Furnishing Exclusion

    For HCPCS J0606, ESRD facilities are not responsible for furnishing calcimimetics to individuals with acute kidney injury (AKI).

    • HCPCS J0606: Injection, etelcalcetide, 0.1 mg, to ESRD beneficiaries.
    • AKI furnishing exclusion applies to calcimimetics furnished by ESRD facilities.
  1. Age: The patient is at least 18 years of age.≥18 years
  2. Calcium status: The patient has a corrected calcium level at or above the lower limit of normal prior to initiation.≥8.3 mg/dl
  3. Concomitant therapy: The patient is taking stable doses of active vitamin D analogs, calcium supplements, or phosphate binders.